Obesity, cardiovascular risk and healthcare resource utilization in the UK

Carel W le Roux1,2, Niels V Hartvig3, Christiane Lundegaard Haase3

  • 1Diabetes Complications Research Centre, Conway Institute, University College Dublin, Ireland.

Insights

Higher body mass index (BMI) and cardiovascular disease (CVD) risk significantly increase healthcare resource utilization (HCRU). Managing obesity and CVD risk factors is crucial for reducing healthcare costs.

Area of Science:

  • Public Health
  • Cardiology
  • Health Economics

Background:

  • Obesity and cardiovascular diseases (CVDs) frequently coexist, potentially escalating healthcare resource utilization (HCRU).
  • Understanding the combined impact of obesity and CVD risk on HCRU is vital for resource allocation and patient management.

Purpose of the Study:

  • To investigate the joint effect of obesity (categorized by BMI) and cardiovascular risk status on HCRU in a UK population.
  • To compare HCRU across different BMI and CVD risk categories.

Main Methods:

  • Retrospective observational study using the UK Clinical Practice Research Datalink.
  • Patients categorized by BMI (WHO classifications) and CVD risk (Framingham Risk Equation: low, high, established CVD).
  • Analysis of general practitioner contacts, hospital admissions, and prescriptions.

Main Results:

  • A study population of 1,600,709 patients was analyzed.
  • Increasing BMI category correlated with higher HCRU across all CVD risk groups.
  • Established CVD group exhibited the highest HCRU, followed by high CVD risk, then low CVD risk groups.

Conclusions:

  • Both increasing BMI and higher CVD risk status significantly impact HCRU components.
  • Timely obesity management and treatment of CVD risk factors are essential for preventing increased HCRU.
Abstract

Related Concept Videos

Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
24
Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
721
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
24
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
28
Assessment of the Cardiovascular System I: Subjective Data01:23

Assessment of the Cardiovascular System I: Subjective Data

A thorough health history and physical assessment are essential for identifying cardiovascular disease (CVD) symptoms and distinguishing them from other health issues.
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
526
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
504